The study is designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of AZD1722 in healthy Japanese subjects at increasing doses given for 7 days in order to allow for including Japanese subjects in future global studies. A cohort of Caucasian subjects will be included in the study to evaluate cardiac effects, assessed by digital ECGs (dECG) recordings, also in Caucasian subjects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
83
WCCT Global
Cypress, California, United States
Number of patients with adverse events
Measurement of safety laboratories, ECGs, vital signs, and physical exams
Time frame: up to 3 weeks
pharmacodynamic activity
24-hour stool sodium and phosphorus
Time frame: up to one week
pharmacokinetics
plasma drug concentration to calculate AUC, if possible
Time frame: up to one week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.